Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Beam Therapeutics Inc is a biotechnology business based in the US. Beam Therapeutics shares (BEAM) are listed on the NASDAQ and all prices are listed in US Dollars. Beam Therapeutics employs 266 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$90.71|
|52-week range||$29.43 - $138.52|
|50-day moving average||$96.97|
|200-day moving average||$89.84|
|Wall St. target price||$128.57|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-7.12|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-12)||3.24%|
|1 month (2021-09-17)||-11.86%|
|3 months (2021-07-19)||0.48%|
|6 months (2021-04-19)||27.96%|
|1 year (2020-10-19)||184.54%|
|2 years (2019-10-15)||N/A|
|3 years (2018-10-15)||N/A|
|5 years (2016-10-15)||N/A|
|Gross profit TTM||$-91,956,000|
|Return on assets TTM||-35.36%|
|Return on equity TTM||-104.63%|
|Market capitalisation||$6.2 billion|
TTM: trailing 12 months
There are currently 5.0 million Beam Therapeutics shares held short by investors – that's known as Beam Therapeutics's "short interest". This figure is 3.5% down from 5.2 million last month.
There are a few different ways that this level of interest in shorting Beam Therapeutics shares can be evaluated.
Beam Therapeutics's "short interest ratio" (SIR) is the quantity of Beam Therapeutics shares currently shorted divided by the average quantity of Beam Therapeutics shares traded daily (recently around 743392.33038348). Beam Therapeutics's SIR currently stands at 6.78. In other words for every 100,000 Beam Therapeutics shares traded daily on the market, roughly 6780 shares are currently held short.
However Beam Therapeutics's short interest can also be evaluated against the total number of Beam Therapeutics shares, or, against the total number of tradable Beam Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Beam Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Beam Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1146% of the tradable shares (for every 100,000 tradable Beam Therapeutics shares, roughly 115 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Beam Therapeutics.
Find out more about how you can short Beam Therapeutics stock.
We're not expecting Beam Therapeutics to pay a dividend over the next 12 months.
Beam Therapeutics Inc. , a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc. ; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.